Partial virological response to three different @entity377 analogues in naive XXXX with @entity6194 .

@entity1 @entity16332 @entity144 @entity377 @entity6194 @entity17705 @entity6372 @entity15833
BACKGROUND: The definition of @entity6372 ( @entity6372 ) was proposed because of its clinical relevance. @entity6372 relates to subsequent therapeutic failure which results in the modification of the regimen. Whether this rationale can be applied to all @entity377 analogues (NA) is not clear. This study was undertaken to analyze @entity6372 influence on therapeutic outcomes during @entity16332 , @entity17705 or @entity15833 monotherapy in NA-naive @entity1 with @entity6194 in routine clinical practice. METHODS: We retrospectively analyzed 150 NA-naive @entity1 with @entity6194 . These subjects received @entity16332 , @entity17705 or @entity15833 monotherapy between February 2001 and July 2013. RESULTS: Sixty-nine @entity1 were treated with @entity16332 , 35 with @entity17705 , and 46 with @entity15833 . The median therapeutic duration was 19.5 (6-147) months. @entity6372 rates at 24 weeks were similar among three @entity144 ( @entity16332 33.3%, @entity17705 35.0%, @entity15833 32.4%, P=0.981). For all three NAs, @entity1 with a higher baseline viral load or HBeAg-positive status had a higher serum viral positive rate tested by polymerase chain reaction at week 24 and 48. Cumulative probability of virological breakthrough (VBR) for @entity1 treated with @entity16332 was 67% at 5 years, and @entity6372 at 24 weeks was the independent risk factor for VBR (HR: 3.09; 95% CI: 1.09-8.74; P=0.034); also @entity16332 treated @entity1 older than 50 years seemed to have a tendency for VBR (HR: 2.80; 95% CI: 0.99-8.18; P=0.052). A majority of @entity17705 and @entity15833 partial responders achieved and maintained virological response with prolonged monotherapy, except one @entity17705 treated @entity1 who experienced VBR due to resistance mutations. CONCLUSIONS: Management strategy for @entity16332 treatment should include adaptation of regimen according to @entity6372 as an on-treatment response parameter due to its relation with unacceptably high VBR probability. Similar conclusion should not be directly related to @entity17705 or @entity15833 treatment.
